EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm

Fernanda Vaisman, Denise Momesso, Daniel A. Bulzico, Cencita H. C. N. Pessoa, Manuel Domingos Gonçalves da Cruz, Fernando Dias, Rossana Corbo, Mario Vaisman, R. Michael Tuttle

Journal of Thyroid Research · 2013 · 2013 · 1-5

DOI: 10.1155/2013/398194 ↗
AbstractBibliografische Angaben

Abstract

Background and Objective . An individualized risk-based approach to the treatment of thyroid cancer is being extensively discussed in the recent literature. However, controversies about the ideal surgical approach remain an important issue with regard to the impact on prognosis and follow-up strategies. This study was designed to describe clinical outcomes in a cohort of low and intermediate risk thyroid cancer patients treated with thyroid lobectomy. Methods . Retrospective review of 70 patients who underwent lobectomy. Results . After a median follow-up of 11 years, 5 patients (5/70, 7.1%) recurred and 5 had a completion for benign lesions, while 60 patients (86%) continued to be observed without evidence for disease recurrence. Suspicious ultrasound findings were significantly more common in patients that had structural disease recurrence (100% versus 4.3%, P < 0.001 ). Furthermore, a rising suppressed Tg value over time was also associated with structural disease recurrence (80% versus 21.5%, P = 0.01 ). After additional therapy, 99% of the patients had no evidence of disease. Conclusions . Properly selected thyroid cancer patients can be treated with lobectomy with excellent clinical outcomes.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →